Diadema Partners LP Relay Therapeutics, Inc. Transaction History
Diadema Partners LP
- $391 Billion
- Q3 2025
A detailed history of Diadema Partners LP transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 43,616 shares of RLAY stock, worth $288,737. This represents 0.06% of its overall portfolio holdings.
Number of Shares
43,616
Previous 43,616
-0.0%
Holding current value
$288,737
Previous $151 Million
50.87%
% of portfolio
0.06%
Previous 0.05%
Shares
3 transactions
Others Institutions Holding RLAY
# of Institutions
215Shares Held
168MCall Options Held
714KPut Options Held
14.9K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$185 Million1.1% of portfolio
-
Commodore Capital LP New York, NY17MShares$113 Million5.66% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct14.8MShares$97.8 Million0.15% of portfolio
-
Casdin Capital, LLC New York, NY11.3MShares$75.1 Million8.07% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$69.8 Million0.0% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $796M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...